Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect and safety of adalimumab in approximately 20 subjects
with mild to moderate psoriasis and sleep apnea and will be conducted in one treatment center
located in Montreal.
Patients with psoriasis often have additional disorders such as obesity. Obese patients are
more at risk of developing obstructive sleep apnea. This is believed to be caused by both the
collapse of upper airways and inflammation (swelling). Adalimumab, a drug currently approved
by Health Canada for the treatment of psoriasis, blocks tumor necrosis factor-alpha
(TNF-alpha). This chemical is present at higher levels in patients with sleep apnea. It is
believed that adalimumab could improve obstructive sleep apnea by lowering the levels of
TNF-alpha.